Valeant Pharma to spend $1 B on maker of drug designed to boost sexual desire in women

Valeant Pharmaceuticals will pay about $1 billion to buy Sprout Pharmaceuticals, the maker of the first prescription drug designed to boost sexual desire in women.

The deal Thursday comes one day after regulators approved the pill.

Valeant expects the Sprout pill, Addyi, to be available in the United States in the fourth quarter. The deal to buy the company should close in this quarter.

The Canadian drugmaker will pay about $500 million at closing for Sprout and then make another milestone-based payment of around $500 million in the first quarter of next year.

News from © The Associated Press, . All rights reserved.
This material may not be published, broadcast, rewritten or redistributed.

Share this story!
Copy to Clipboard Share on Facebook Share on X (Twitter) Share on LinkedIn Share on WhatsApp Share on Threads Share on Email

Join the Conversation!

Want to share your thoughts, add context, or connect with others in your community?

The Associated Press

The Associated Press is an independent global news organization dedicated to factual reporting. Founded in 1846, AP today remains the most trusted source of fast, accurate, unbiased news in all formats and the essential provider of the technology and services vital to the news business. More than half the world’s population sees AP journalism every day.